LTGONasdaqPharmaceutical PreparationsUS GAAP · USD

Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing non-opioid medicines for pain and related conditions. Its business model centers on discovering, advancing and potentially commercializing proprietary small-molecule product candidates through preclinical and clinical development, supported by intellectual property, contract research and manufacturing partners.

Ask about the company

Business

Share of revenue
Pain therapeutics70 %

Proprietary non-opioid product candidates intended to address pain-related conditions.

Preclinical development10 %

Laboratory research, candidate selection and studies supporting advancement into clinical testing.

Clinical development15 %

Clinical trials and related development activities required to establish safety and efficacy.

Licensing and collaborations5 %

Potential future revenue from licensing rights, collaborations, milestones or royalties.

Customers

Latigo currently has no commercial product and has not generated revenue, so its immediate external stakeholders are clinical research organizations, contract manufacturers, investigators, regulators and collaboration partners rather than product purchasers. If candidates are approved, potential customers would include healthcare providers and physicians prescribing pain medicines, third-party payors funding treatment, hospitals and specialty pharmacies. Commercial access would depend on clinical differentiation, regulatory approval, pricing and reimbursement.

Clinical research organizations

Conduct preclinical studies and clinical trials under outsourced development agreements.

Contract manufacturers

Produce clinical and potentially commercial supplies to required quality standards.

Healthcare providers

Would prescribe approved non-opioid pain medicines based on clinical utility and safety.

Third-party payors

Would evaluate coverage, pricing and reimbursement for approved products.

Licensing and collaboration partners

May provide development, commercialization or regional capabilities and funding.

Strategy

Latigo’s strategy is to advance its product candidates through preclinical and clinical development while protecting the underlying intellectual property. The company expects to use contract research and manufacturing organizations, selected partnerships and additional capital to progress programs toward regulatory approval. If a candidate is approved, Latigo would need to build internal commercial capabilities or partner with companies that have established sales, marketing and distribution infrastructure.

Advance clinical and preclinical programsShort term

Clinical evidence is required to establish safety, efficacy and regulatory value.

Secure development fundingShort term

The company requires substantial capital before potential product revenue begins.

Protect intellectual propertyMedium term

Patent protection supports exclusivity and the future commercial value of candidates.

Prepare for commercializationLong term

Approval would require capabilities that Latigo does not currently possess internally.

Geography

Latigo is headquartered in the United States and conducts its business under the U.S. pharmaceutical and securities regulatory framework. Its development model can involve research organizations, trial sites, manufacturers and regulators in the United States and other countries, but the provided reports do not disclose country-level revenue or operating shares. Geographic expansion would increase regulatory, supply-chain, reimbursement and compliance complexity.

Risks

Latigo faces the high uncertainty typical of a clinical-stage biotechnology company: candidates may fail in development, encounter regulatory delays or lack commercial differentiation. The company relies on third parties for trials and manufacturing, while additional capital is needed to sustain operations and advance programs. Even after approval, commercialization would depend on reimbursement, compliant healthcare-provider relationships and effective sales and distribution capabilities.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Need for additional capital1Clinical and regulatory failure2Dependence on external providers3Intellectual property disputes4Commercialization execution5Healthcare compliance6
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Need for additional capitalImpact: CriticalLikelihood: High

    Latigo has no meaningful revenue and cannot fund development and commercialization solely from operations.

    Exposure: Company-wide development programs

  2. Clinical and regulatory failureImpact: CriticalLikelihood: Medium

    Product candidates may fail trials or face delays, rejection or additional testing requirements.

    Exposure: All preclinical and clinical programs

  3. Dependence on external providersImpact: HighLikelihood: Medium

    CROs, investigators and CMOs must meet quality, timing and regulatory requirements.

    Exposure: Clinical trials and product supply

  4. Intellectual property disputesImpact: HighLikelihood: Low

    Patents may be challenged, invalidated or found unenforceable, weakening exclusivity.

    Exposure: Owned and in-licensed technology

  5. Commercialization executionImpact: HighLikelihood: Low

    The company has no internal sales, marketing or distribution capabilities.

    Exposure: Future approved products

  6. Healthcare complianceImpact: HighLikelihood: Low

    Anti-kickback, fraud and abuse rules constrain provider, payor and customer arrangements.

    ExposureResearchPromotionFuture sales
Ask Clarifo about Latigo Biotherapeutics, Inc.

Accounting

Judgemental items
Research and development accruals

Clinical, CRO and manufacturing services may be incurred before invoices are received.

Impact: Can materially change period expenses and accrued liabilities.

Preclinical and clinical cost allocation

Internal costs span multiple programs while external costs are tracked by development stage.

Impact: Affects program-level expense analysis and period comparability.

Revenue recognition

The company has not generated revenue and expects meaningful revenue only after approval and commercialization.

Impact: Reported results currently reflect development spending rather than product sales.

Stock-based compensation

Equity awards are common in development-stage biotechnology companies.

Impact: Increases reported operating expenses and may dilute shareholders.

Vendor commitments and contingencies

CRO and CMO agreements may include cancellation or termination payments.

Impact: Could create unexpected liabilities when programs or contracts change.

Similar listed companies

Publicly listed companies with a comparable business focus.

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Passage BIO, Inc.

PASG · Biological Products, (No Diagnostic Substances)

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

MAIA Biotechnology, Inc.

MAIA · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Last updated: 24/09/2026